Literature DB >> 23060914

Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy.

Kiyoshi Kikuchi1, Ko-Ichi Kawahara, Naoki Miura, Takashi Ito, Yoko Morimoto, Salunya Tancharoen, Nobuyuki Takeshige, Hisaaki Uchikado, Rokudai Sakamoto, Naohisa Miyagi, Chiemi Kikuchi, Narumi Iida, Naoto Shiomi, Terukazu Kuramoto, Masaru Hirohata, Ikuro Maruyama, Motohiro Morioka, Eiichiro Tanaka.   

Abstract

Stroke is a major cause of mortality and disability worldwide. During the past three decades, major advances have occurred in secondary prevention, which have demonstrated the broader potential for the prevention of stroke. Risk factors for stroke include previous stroke or transient ischemic attack, hypertension, high blood cholesterol and diabetes. Proven secondary prevention strategies are anti-platelet agents, antihypertensive drugs, statins and glycemic control. In the present review, we evaluated the secondary prevention of stroke in light of clinical studies and discuss new pleiotropic effects beyond the original effects and emerging clinical evidence, with a focus on the effect of optimal oral pharmacotherapy.

Entities:  

Year:  2012        PMID: 23060914      PMCID: PMC3460248          DOI: 10.3892/etm.2012.560

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  46 in total

1.  Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

Authors:  Yutaka Mori; Yohta Itoh; Tohru Obata; Naoko Tajima
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.

Authors:  Keisuke Fujitaka; Hajime Otani; Fusakazu Jo; Hiromi Jo; Emiko Nomura; Masayoshi Iwasaki; Mitsushige Nishikawa; Toshiji Iwasaka
Journal:  Endocr J       Date:  2011-04-17       Impact factor: 2.349

3.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.

Authors:  F A Araújo; M A Rocha; J B Mendes; S P Andrade
Journal:  Biomed Pharmacother       Date:  2009-09-08       Impact factor: 6.529

6.  The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.

Authors:  Bonnie Ky; Anne Burke; Sotirios Tsimikas; Megan L Wolfe; Mahlet G Tadesse; Philippe O Szapary; Joseph L Witztum; Garret A FitzGerald; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-04-29       Impact factor: 24.094

Review 7.  Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

Authors:  Joseph B Muhlestein
Journal:  Thromb Haemost       Date:  2009-11-13       Impact factor: 5.249

Review 8.  Secondary stroke prevention: from guidelines to clinical practice.

Authors:  Glenn D Graham
Journal:  J Natl Med Assoc       Date:  2008-10       Impact factor: 1.798

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS).

Authors:  Shinichiro Uchiyama; Nobuyuki Sakai; Sono Toi; Masayuki Ezura; Yasushi Okada; Makoto Takagi; Yoji Nagai; Yoshihiro Matsubara; Kazuo Minematsu; Norihiro Suzuki; Norio Tanahashi; Waro Taki; Izumi Nagata; Masayasu Matsumoto
Journal:  Cerebrovasc Dis Extra       Date:  2015-01-15
View more
  1 in total

1.  Mechanically assisted intra-arterial thrombolysis in acute cerebral infarction.

Authors:  Hui-Xiao Wang; Yi-Jin Shen; Shu-Jun Ye; Yong-Kang Xu; Jian-Pin Zhang; Zhou Lu
Journal:  Exp Ther Med       Date:  2013-03-06       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.